Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Friday, November 18, 2022
Pfizer and BioNTech announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (...
read more
Monday, November 14, 2022
BioNTech announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing to acquire one of its GMP-certified ...
read more
Thursday, November 10, 2022
Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 5/5-µg) is now recommended for marketing authorization ...
read more
Wednesday, November 09, 2022
Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company's BA.1 vaccine candidate (NVX-CoV2515) met the primary ...
read more
Wednesday, November 09, 2022
FDA has issued an emergency use authorization (EUA) for Kineret (anakinra) injection for the treatment of COVID-19 in hospitalized adults with pneumonia requiring supplemental oxygen (low- or high-...
read more
Friday, November 04, 2022
Health Canada has authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron BA.4/BA.5 subvariants. It is authorized for use as a booster dose in individuals 18 ...
read more
Friday, November 04, 2022
Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg booster dose of the companies’ Omicron BA.4/BA.5-...
read more
Wednesday, October 26, 2022
Codagenix, in collaboration with the Serum Institute of India, announced dosing has been initiated in an international, multi-center, randomized placebo-controlled Phase 3 clinical trial of CoviLiv.
read more
Sartorius entered a research partnership with The BASE Facility at The University of Queensland (UQ) to improve the manufacturing process of nucleic acid products led by the external collaboration ...
read more
Thursday, October 20, 2022
Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the FDA to provide a first booster dose at least six months after ...
read more
Wednesday, October 19, 2022
AstraZeneca's Evusheld™ (tixagevimab and cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the treatment of mild to moderate COVID-19 in adults...
read more
Thursday, October 13, 2022
Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the afety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID...
read more
Thursday, October 13, 2022
The FDA amended the EUAs of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups.
read more
Tuesday, October 11, 2022
CSafe and BioLife Solutions, Inc. announced a new partnership to provide a combined global service network to support CGT products, with a focus on enhanced reliability, security and quality.
read more
Pfizer Canada and BioNTech announced that Health Canada authorized COMIRNATY Original & Omicron BA.4/BA.5 as a 30-µg booster dose for individuals ages 12 years and older.
read more